CAR T-cell Therapy | Specialty

Axicabtagene Ciloleucel Approaches EU Approval for DLBCL, PMBCL

June 29th 2018

The European Medicines Agency’s CHMP has recommended approval of axicabtagene ciloleucel (axi-cel; Yescarta) as a treatment for adult patients with relapsed/refractory diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma.

Tisagenlecleucel Nears European Approval for DLBCL, ALL

June 29th 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of tisagenlecleucel for the treatment of either adult patients with diffuse large B-cell lymphoma that is relapsed or refractory after 2 or more lines of systemic therapy, or patients up to 25 years of age with B-cell acute lymphoblastic leukemia that is refractory, in relapse posttransplant, or in second or later relapse.

Dr. Raje Discusses the Tolerability of bb2121 in Myeloma

June 25th 2018

Noopur Raje, MD, director Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, discusses the tolerability of bb2121 as a treatment for patients with multiple myeloma.

Dr. Borchmann Discusses the Updated Analysis of JULIET in DLBCL

June 21st 2018

Peter Borchmann, MD, professor, University Hospital of Cologne, Cologne, Germany, discusses the updated analysis of the JULIET trial in patients with diffuse large B-cell lymphoma (DLBCL).

Tisagenlecleucel Demonstrates Durable Response Beyond 1 Year in DLBCL

June 17th 2018

At a median follow-up of 14.1 months, the chimeric antigen receptor T-cell therapy tisagenlecleucel achieved an objective response rate of 52% in adult patients with relapsed/refractory diffuse large B-cell lymphoma.

CD22 CAR T-cell Therapy Effective After CD19 CAR Therapy Failure in Children With B-ALL

June 16th 2018

A CAR T-cell therapy specific for CD22 was safe and provided high response rates for pediatric patients with B-cell acute lymphoblastic leukemia who had failed chemotherapy and/or a CD19-targeted CAR T-cell treatment.

Update Sustains Liso-Cel as Strong Contender in CAR T-Cell Space

June 14th 2018

The CD19-directed chimeric antigen receptor T-cell therapy lisocabtagene maraleucel (JCAR017; liso-cel) is showing promising response rates in patients with high-risk diffuse large B-cell lymphoma.

CAR T-Cell Therapy: The Sticker Price Is Just for Openers

June 12th 2018

CMS has proposed a different way to handle payment for chimeric antigen receptor T-cell therapy, one that the medical and manufacturing community thinks is unworkable.

CAR T-Cell Therapy Explored in Mantle Cell Lymphoma

June 7th 2018

The CD19-targeted CAR T-cell product axicabtagene ciloleucel (axi-cel; Yescarta) is currently being investigated in patients with relapsed/refractory MCL in the ongoing ZUMA-2 trial.

ASCO Studies Refine CAR T Cell Use

June 7th 2018

Several studies presented at the 2018 ASCO Annual Meeting helped further refine and inform treatment strategies for the budding class of CAR T-cell therapies, with a focus on predicting adverse events and optimizing efficacy.

bb2121 Adds Nearly 1 Year of PFS for Heavily Pretreated Myeloma

June 2nd 2018

bb2121 had a median progression-free survival of 11.8 months and a median duration of response of 10.8 months for patients with relapsed/refractory heavily pretreated multiple myeloma.

CAR T-Cell Therapy in DLBCL: Centers of Excellence

May 25th 2018

DLBCL: Managing Toxicities of CAR T-Cell Therapy

May 25th 2018

Response Data from the JULIET Trial in DLBCL

May 25th 2018

Lymphodepletion for CAR T-Cell Therapies in DLBCL

May 25th 2018

Selecting from CAR T-Cell Therapies in DLBCL

May 25th 2018

Candidates for CAR T-Cell Therapy in DLBCL

May 25th 2018

Future Outlook of CAR T-Cell Therapy for DLBCL

May 25th 2018

Practical Implications of CAR T-Cell Therapy

May 25th 2018

Clinical Significance of the JULIET Trial

May 25th 2018